NYU Langone Aims to Transform Cancer Care Through Advanced Molecular Profiling
Business Wire
|
Contributed by: Kate Gamble
Summary
Tempus has partnered with NYU Langone Health to enhance precision oncology through advanced molecular profiling and data-driven insights at the Center for Molecular Oncology. This collaboration includes a prospective study on "Serial Molecular Profiling and Monitoring of Human Cancer," which will track patients' genomic information throughout their treatment to build critical longitudinal data. The initiative aims to improve genomic diagnostics, patient outcomes, and the development of novel cancer assays and predictive algorithms, highlighting a significant step in integrating AI and precision medicine into cancer care. This partnership underscores the importance of leveraging advanced technology to facilitate better clinical decisions in oncology.
